Technology evaluation: Allovectin-7, Vical

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Allovectin-7 is a gene transfer product consisting of the human leukocyte antigen HLA-B7 gene co-expressed with the β2-microglobulin gene. Allovectin-7 is being developed as an immunotherapy approach for a variety of malignancies, with special focus on melanoma, and head and neck cancer. Efficacy results in the phase II setting appear to be promising; an 11% systemic response rate among the intent-to-treat population and 15% response rate in the evaluable population was observed in patients with refractory metastatic melanoma with disease limited to skin, lymph nodes and lung. Stable disease was seen in 19.2% of the intent-to-treat population and 25.9% of the evaluable population in the same group of patients. Treatments has been extremely well tolerated with the most common side effects including mild-to-moderate injection site reactions and flu-like symptons, all of which resolved rapidly and decreased in incidence after the first injection. Current evaluation of the drug includes higher Allovectin-7 doses and injection of multiple tumors in metastatic melonoma patients. A phase III trial comparing Allovectin-7 plus dacarbazine versus dacarbazine in untreated patients with metastatic melanoma has been completed, and preliminary results are soon to be reported. Phase I/II data also indicate promising activity of Allovectin-7 in patients with advanced refractory head and neck squamous cell carcinoma, with 10% of 60 patients achieving partial response and 23% stable disease after one cycle of treatment. Trials of Allovectin-7 as an adjuvant treatment in earlier stages of disease evolution are planned.

Original languageEnglish (US)
Pages (from-to)80-87
Number of pages8
JournalCurrent Opinion in Molecular Therapeutics
Volume4
Issue number1
StatePublished - 2002

Fingerprint

Technology
Melanoma
Dacarbazine
Population
Injections
HLA-B7 Antigen
Genes
Drug Evaluation
Head and Neck Neoplasms
HLA Antigens
Immunotherapy
Allovectin-7
Neoplasms
Therapeutics
Lymph Nodes
Lung
Skin
Incidence

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Technology evaluation : Allovectin-7, Vical. / Galanis, Evanthia.

In: Current Opinion in Molecular Therapeutics, Vol. 4, No. 1, 2002, p. 80-87.

Research output: Contribution to journalArticle

@article{38446ff7531d4867b8da638a0c8b745e,
title = "Technology evaluation: Allovectin-7, Vical",
abstract = "Allovectin-7 is a gene transfer product consisting of the human leukocyte antigen HLA-B7 gene co-expressed with the β2-microglobulin gene. Allovectin-7 is being developed as an immunotherapy approach for a variety of malignancies, with special focus on melanoma, and head and neck cancer. Efficacy results in the phase II setting appear to be promising; an 11{\%} systemic response rate among the intent-to-treat population and 15{\%} response rate in the evaluable population was observed in patients with refractory metastatic melanoma with disease limited to skin, lymph nodes and lung. Stable disease was seen in 19.2{\%} of the intent-to-treat population and 25.9{\%} of the evaluable population in the same group of patients. Treatments has been extremely well tolerated with the most common side effects including mild-to-moderate injection site reactions and flu-like symptons, all of which resolved rapidly and decreased in incidence after the first injection. Current evaluation of the drug includes higher Allovectin-7 doses and injection of multiple tumors in metastatic melonoma patients. A phase III trial comparing Allovectin-7 plus dacarbazine versus dacarbazine in untreated patients with metastatic melanoma has been completed, and preliminary results are soon to be reported. Phase I/II data also indicate promising activity of Allovectin-7 in patients with advanced refractory head and neck squamous cell carcinoma, with 10{\%} of 60 patients achieving partial response and 23{\%} stable disease after one cycle of treatment. Trials of Allovectin-7 as an adjuvant treatment in earlier stages of disease evolution are planned.",
author = "Evanthia Galanis",
year = "2002",
language = "English (US)",
volume = "4",
pages = "80--87",
journal = "Current Opinion in Molecular Therapeutics",
issn = "1464-8431",
publisher = "Current Drugs Ltd.",
number = "1",

}

TY - JOUR

T1 - Technology evaluation

T2 - Allovectin-7, Vical

AU - Galanis, Evanthia

PY - 2002

Y1 - 2002

N2 - Allovectin-7 is a gene transfer product consisting of the human leukocyte antigen HLA-B7 gene co-expressed with the β2-microglobulin gene. Allovectin-7 is being developed as an immunotherapy approach for a variety of malignancies, with special focus on melanoma, and head and neck cancer. Efficacy results in the phase II setting appear to be promising; an 11% systemic response rate among the intent-to-treat population and 15% response rate in the evaluable population was observed in patients with refractory metastatic melanoma with disease limited to skin, lymph nodes and lung. Stable disease was seen in 19.2% of the intent-to-treat population and 25.9% of the evaluable population in the same group of patients. Treatments has been extremely well tolerated with the most common side effects including mild-to-moderate injection site reactions and flu-like symptons, all of which resolved rapidly and decreased in incidence after the first injection. Current evaluation of the drug includes higher Allovectin-7 doses and injection of multiple tumors in metastatic melonoma patients. A phase III trial comparing Allovectin-7 plus dacarbazine versus dacarbazine in untreated patients with metastatic melanoma has been completed, and preliminary results are soon to be reported. Phase I/II data also indicate promising activity of Allovectin-7 in patients with advanced refractory head and neck squamous cell carcinoma, with 10% of 60 patients achieving partial response and 23% stable disease after one cycle of treatment. Trials of Allovectin-7 as an adjuvant treatment in earlier stages of disease evolution are planned.

AB - Allovectin-7 is a gene transfer product consisting of the human leukocyte antigen HLA-B7 gene co-expressed with the β2-microglobulin gene. Allovectin-7 is being developed as an immunotherapy approach for a variety of malignancies, with special focus on melanoma, and head and neck cancer. Efficacy results in the phase II setting appear to be promising; an 11% systemic response rate among the intent-to-treat population and 15% response rate in the evaluable population was observed in patients with refractory metastatic melanoma with disease limited to skin, lymph nodes and lung. Stable disease was seen in 19.2% of the intent-to-treat population and 25.9% of the evaluable population in the same group of patients. Treatments has been extremely well tolerated with the most common side effects including mild-to-moderate injection site reactions and flu-like symptons, all of which resolved rapidly and decreased in incidence after the first injection. Current evaluation of the drug includes higher Allovectin-7 doses and injection of multiple tumors in metastatic melonoma patients. A phase III trial comparing Allovectin-7 plus dacarbazine versus dacarbazine in untreated patients with metastatic melanoma has been completed, and preliminary results are soon to be reported. Phase I/II data also indicate promising activity of Allovectin-7 in patients with advanced refractory head and neck squamous cell carcinoma, with 10% of 60 patients achieving partial response and 23% stable disease after one cycle of treatment. Trials of Allovectin-7 as an adjuvant treatment in earlier stages of disease evolution are planned.

UR - http://www.scopus.com/inward/record.url?scp=0036079798&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036079798&partnerID=8YFLogxK

M3 - Article

C2 - 11883699

AN - SCOPUS:0036079798

VL - 4

SP - 80

EP - 87

JO - Current Opinion in Molecular Therapeutics

JF - Current Opinion in Molecular Therapeutics

SN - 1464-8431

IS - 1

ER -